SAN DIEGO / Nov 24, 2025 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the following investor conferences in December.
Piper Sandler 37th Annual Healthcare Conference
Date / Time: | December 2nd, at 9:00 AM ET |
Format: | Presentation & 1x1’s |
Location: | New York, NY |
Oppenheimer Movers in Rare Disease Summit
Date / Time: | December 11th, at 9:00 AM ET |
Format: | Panel & 1x1’s |
Location: | New York, NY |
About Gossamer Bio
Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension.
| Last Trade: | US$3.14 |
| Daily Change: | -0.20 -5.99 |
| Daily Volume: | 5,139,100 |
| Market Cap: | US$726.780M |
November 05, 2025 September 25, 2025 September 22, 2025 August 29, 2025 August 05, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
